fashion -WSS

fashion

author：leisure time 2025-10-02 11:07:35 - browse：72

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The cancer stories no one wants to hear

hotspot

WSS

Male and female sex labels in research insufficient, scientists say

FDA approves Sage Therapeutics’ rapid

First U.S. drug developed to treat liver disease MASH is approved

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Heart disease in astronauts blamed on cosmic radiation

The a glaring gap in research on serious mental illness and primary care

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves Sage Therapeutics’ rapid

Apple is now the first public company to be valued at $3 trillion

FDA approves Sage Therapeutics’ rapid

Medicare proposal to cover medical devices draws a mixed reaction

'Null' research findings aren't empty of meaning. Let's publish them

Guidelines to prevent youth baseball injuries need more muscle

CDC recommends RSV monoclonal antibody for infants

ChatGPT in medicine: STAT answers readers' burning questions

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Steward Health Care Massachusetts hospitals face fiscal disaster

WuXi out of biotech trade group, U.S. and China relations to blame

It costs an awful lot of money to give away a kidney

Male and female sex labels in research insufficient, scientists say

Steward Health Care Massachusetts hospitals face fiscal disaster

entertainment

entertainment

hotspot

leisure time